Source-grounded facts extracted from MEDIFAST INC's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Jason L. Groves resigned as Chief Legal Officer & Corporate Secretary at MEDIFAST INC.
“Effective as of May 29, 2026, Jason L. Groves, Esq., the Chief Legal Officer & Corporate Secretary of Medifast, Inc. (the “Company”), tendered his resignation from the Company.”
MEDIFAST INC shareholders approved Approval of Amended and Restated 2012 Share Incentive Plan at the 2026-05-19 meeting.
“The stockholders voted on a proposal to approve the Amended 2012 Plan. The proposal was approved by a vote of the stockholders as follows: For: 3,195,078 Against: 1,442,997 Abstained: 11,018 Broker Non-Votes: 1,840,102”
MEDIFAST INC shareholders approved Advisory Vote to Approve Named Executive Officer Compensation at the 2026-05-19 meeting.
“The stockholders voted on a proposal to approve, on an advisory basis, the compensation of the Company’s named executive officers as set forth in the proxy statement for the Annual Meeting. The proposal was approved by a vote of the stockholders as follows: For: 3,996,046 Against: 637,173 Abstained: 15,874 Broker Non-Votes: 1,840,102”
MEDIFAST INC shareholders approved Ratification of Appointment of RSM US LLP as Independent Registered Public Accounting Firm for Fiscal Year 2026 at the 2026-05-19 meeting.
“The stockholders voted on a proposal to ratify the appointment of RSM US LLP as the Company’s Independent Registered Public Accounting Firm for the fiscal year ending December 31, 2026. The proposal was approved by a vote of stockholders as follows: For: 6,411,175 Against: 53,444 Abstained: 24,576”
MEDIFAST INC shareholders approved Election of Directors at the 2026-05-19 meeting.
“The number of shares voted and broker non-votes for the directors nominated for election to the Board are set forth below. Director Name For Against Abstained Broker Non-Votes Daniel R. Chard 4,377,045 261,811 10,237 1,840,102 Elizabeth A. Geary 4,313,878 323,551 11,664 1,840,102 Parsa Kiai 4,378,697 259,279 11,117 1,840,102 Jeffrey Rose 4,398,976 238,929 11,188 1,840,102 Scott Schlackman 3,842,303 795,603 11,187 1,840,102 Andrea B. Thomas 4,260,999 378,012 10,082 1,840,102 Ming Xian 4,275,817 356,337 16,939 1,840,102”
Nicholas Johnson was appointed as Chief Executive Officer at MEDIFAST INC.
“On May 20, 2026, the Board appointed Nicholas Johnson, age 46, to serve as Chief Executive Officer of the Company, effective June 1, 2026.”
MEDIFAST INC reported the first quarter ended March 31, 2026 results: revenue $76.0 million, net income $2.1 million, EPS $0.19 per diluted share. Guidance initiated.
“Medifast Announces First Quarter 2026 Financial Results May 4, 2026 BALTIMORE – ( BUSINESS WIRE )-- Medifast (NYSE: MED), the metabolic health and wellness company known for its science-backed, coach-guided lifestyle system, today reported results for the first quarter ended March 31, 2026. First Quarter 2026 • Revenue of $76.0 million, with revenue per active earning coach of $5,432 • Independent active earning coaches of 14,000 • Net loss of $2.1 million, or $0.19 per diluted share ("EPS") • Cash, Cash Equivalents, and Investment Securities of $168.9 million with no debt”
MEDIFAST INC entered into Cooperation Agreement with Steamboat Capital Partners LLC and certain of its related persons (effective 2026-03-19).
“On March 19, 2026, Medifast, Inc. (the "Company") and Steamboat Capital Partners LLC and certain of its related persons ("Steamboat") entered into a Cooperation Agreement (the "Cooperation Agreement").”
MEDIFAST INC reported first quarter ended March 31, 2024 results: revenue $174.7 million, net income $8.3 million, EPS $0.76 per diluted share.
“Medifast (NYSE: MED), the health and wellness company known for its habit-based and Coach-guided lifestyle solution, OPTA VIA®, today reported results for the first quarter ended March 31, 2024. First Quarter 2024 • Revenue of $174.7 million, with revenue per active earning coach of $4,623 • Independent active earning OPTA VIA Coaches of 37,800 • Net income of $8.3 million (non-GAAP adjusted net income of $7.2 million) • Earnings per diluted share ("EPS") of $0.76 (non-GAAP adjusted EPS of $0.66)”
MEDIFAST INC reported Full Year 2023 results: revenue $1.1 billion, net income $99.4 million, EPS $9.10.
“Full Year 2023 • Revenue of $1.1 billion • Net income of $99.4 million (non-GAAP adjusted net income of $105.2 million) • EPS of $9.10 (non-GAAP adjusted EPS of $9.64)”
MEDIFAST INC reported fourth quarter and full year ended December 31, 2023 results: revenue $191.0 million, net income $6.0 million, EPS $0.55 per diluted share.
“Medifast (NYSE: MED), the health and wellness company known for its habit-based and Coach-guided lifestyle solution, OPTA VIA®, today reported results for the fourth quarter and full year ended December 31, 2023. Fourth Quarter 2023 • Revenue of $191.0 million, with revenue per active earning Coach of $4,648 • Independent active earning OPTA VIA Coaches of 41,100 • Net income of $6.0 million (non-GAAP adjusted net income of $11.9 million) • Earnings per diluted share ("EPS") of $0.55 (non-GAAP adjusted EPS of $1.09) Full Year 2023 • Revenue of $1.1 billion • Net income of $99.4 million (non-GAAP adjusted net income of $105.2 million) • EPS of $9.10 (non-GAAP adjusted EPS of $9.64) • Cash, Cash Equivalents, and Investments of $150.0 million and no interest-bearing debt”
MEDIFAST INC reported third quarter ended September 30, 2023 results: revenue Revenue of $235.9 million, net income Net income of $23.1 million, EPS Earnings per diluted share ("EPS") of $2.12.
“Medifast Announces Third Quarter 2023 Financial Results November 6, 2023 BALTIMORE--(BUSINESS WIRE)-- Medifast (NYSE: MED), the health and wellness company known for its habit-based and Coach-guided lifestyle solution, OPTA VIA®, today reported results for the third quarter ended September 30, 2023. Third Quarter 2023 • Revenue of $235.9 million, with revenue per active earning Coach of $5,008 • Independent active earning OPTA VIA Coaches of 47,100 • Net income of $23.1 million • Earnings per diluted share ("EPS") of $2.12”
MEDIFAST INC reported third quarter 2023 results: revenue $220 million to $240 million, EPS $0.71 to $1.32. Guidance initiated.
“The Company expects third quarter 2023 revenue to be in the range of $220 million to $240 million and third quarter 2023 diluted EPS to be in the range of $0.71 to $1.32”
MEDIFAST INC reported second quarter ended June 30, 2023 results: revenue $296.2 million, net income $30.3 million, EPS $2.77 per diluted share.
“known for its habit-based and Coach-guided lifestyle solution, OPTA VIA® , today reported results for the second quarter ended June 30, 2023 . Second Quarter 2023 • Revenue of $296.2 million, with revenue per active earning coach of $5,578 • Independent active earning OPTA VIA Coaches of 53,100 • Net income of $30.3 million • Earnings per diluted share ("EPS) of”
MEDIFAST INC shareholders approved Advisory vote on frequency of say-on-pay votes at the 2023-06-14 meeting.
“The stockholders voted on a proposal to approve, on an advisory basis, a frequency of one-year of the advisory vote on executive compensation. The proposal was approved for an annual vote by a vote of the stockholders as follows: Once Every Year: 7,528,144 Once Every 2 Years: 36,611 Once Every 3 Years: 354,240 Abstained: 36,377 Broker Non-Votes: 1,059,865”
MEDIFAST INC shareholders approved Advisory approval of named executive officer compensation at the 2023-06-14 meeting.
“The stockholders voted on a proposal to approve, on an advisory basis, the compensation of the Company’s named executive officers as set forth in the proxy statement for the Annual Meeting. The proposal was approved by a vote of the stockholders as follows: For: 7,495,497 Against: 372,673 Abstained: 87,201 Broker Non-Votes: 1,059,866”
MEDIFAST INC shareholders approved Ratify appointment of RSM US LLP as Independent Registered Public Accounting Firm for fiscal year ending December 31, 2023 at the 2023-06-14 meeting.
“The stockholders voted on a proposal to ratify the appointment of RSM US LLP as the Company’s Independent Registered Public Accounting Firm for the fiscal year ending December 31, 2023. The proposal was approved by a vote of stockholders as follows: For: 8,949,489 Against: 55,282 Abstained: 10,466”
MEDIFAST INC shareholders approved Election of directors at the 2023-06-14 meeting.
“The number of shares voted and broker non-votes for the directors nominated for re-election to the Board are set forth below. Director Name For Against Abstained Broker Non-Votes Jeffrey J. Brown 7,690,887 234,232 30,252 1,059,866 Daniel R. Chard 7,656,983 278,797 19,591 1,059,866 Elizabeth A. Geary 7,849,710 77,812 27,849 1,059,866 Michael A. Hoer 7,846,691 81,211 27,469 1,059,866 Scott Schlackman 7,810,395 117,616 27,360 1,059,866 Andrea B. Thomas 7,387,316 532,634 35,421 1,059,866 Ming Xian 7,542,094 385,088 28,189 1,059,866”
MEDIFAST INC reported the first quarter ended March 31, 2023 results: revenue $349.0 million, net income $40.0 million, EPS $3.67 per diluted share.
“Medifast (NYSE: MED), the global company behind one of the fastest-growing health and wellness communities, OPTA VIA® , today reported results for the first quarter ended March 31, 2023. First Quarter 2023 • Revenue of $349.0 million, with revenue per active earning coach of $5,945 • Independent active earning OPTA VIA Coaches of 58,700 • Net income of $40.0 million • Earnings per diluted share (“EPS”) of $3.67”
Lauren Walker retired as Executive Vice President, Supply Chain at MEDIFAST INC.
“On March 13, 2023, Lauren Walker, Executive Vice President, Supply Chain of Medifast, Inc. (the "Company") informed the Company of her intention to retire, effective May 4, 2023.”
MEDIFAST INC reported the fiscal year ended December 31, 2022 results: revenue $1.6 billion, net income $143.6 million, EPS $12.73 per diluted share. Guidance reaffirmed.
“For the fiscal year ended December 31, 2022, revenue increased 4.8% to $1.6 billion compared to revenue of $1.5 billion in 2021.”
MEDIFAST INC reported the fourth quarter ended December 31, 2022 results: revenue $337.2 million, net income $26.5 million, EPS $2.41 per diluted share.
“one of the fastest-growing health and wellness communities, OPTA VIA® , today reported results for the fourth quarter ended December 31, 2022. Fourth Quarter 2022 • Revenue of $337.2 million, with revenue per active earning coach of $5,538 • Independent active earning OPTA VIA Coaches of 60,900 • Net income of $26.5 million (non-GAAP adjusted net income of $40.6”
MEDIFAST INC reported full-year 2022 results: revenue $1.51 billion to $1.59 billion, EPS $11.61 to $13.05. Guidance lowered.
“The company now anticipates that full-year 2022 revenue to be in the range of $1.51 billion to $1.59 billion, down from the previously announced range of $1.58 billion to $1.66 billion that was previously disclosed. The company expects full-year 2022 non-GAAP diluted EPS to be in the range of $11.61 to $13.05, down from the previously announced range of $12.70 to $14.10.”
MEDIFAST INC reported the third quarter ended September 30, 2022 results: revenue $390.4 million, net income $36.2 million, EPS $3.27 per diluted share.
“Medifast (NYSE: MED), the global company behind one of the fastest-growing health and wellness communities, OPTA VIA® , today reported results for the third quarter ended September 30, 2022. Third Quarter 2022 • Revenue of $390.4 million, with revenue per active earning coach of $5,897 • Independent active earning OPTA VIA Coaches of 66,200 • Net income of $36.2 million (non-GAAP adjusted net income of $36.8 million) • Earnings per diluted share of $3.27 (non-GAAP adjusted EPS of $3.32)”
James P. Maloney changed role as Interim Chief Accounting Officer at MEDIFAST INC.
“Mr. MacKenzie succeeds James P. Maloney, who will cease to serve as the Company’s Interim Chief Accounting Officer upon the effectiveness of Mr. MacKenzie’s employment.”
Jonathan B. MacKenzie was appointed as Chief Accounting Officer at MEDIFAST INC.
“Effective as of September 13, 2021, the Board of Directors of Medifast, Inc. (the “Company”) appointed Jonathan B. MacKenzie to serve as Chief Accounting Officer of the Company.”
Stephen K. Johnson departed as Chief Accounting Officer at MEDIFAST INC.
“reported the departure of Stephen K. Johnson, the Company’s Chief Accounting Officer, effective August 5, 2021.”
James P. Maloney was appointed as interim principal accounting officer at MEDIFAST INC.
“James P. Maloney, the Company’s Chief Financial Officer, will serve as interim principal accounting officer as of the effective date of Mr. Johnson’s resignation.”
Stephen K. Johnson resigned as Chief Accounting Officer at MEDIFAST INC.
“On August 5, 2021, Medifast, Inc. (the “Company”) and Stephen K. Johnson, the Company’s Chief Accounting Officer, agreed that Mr. Johnson will depart from his position as Chief Accounting Officer and all other positions that he holds as an officer or employee of the Company, effective August 5, 2021.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.